Star Health & Allied Insurance Company Ltd

The document does not mention any current or planned future fundraising activities through debt or equity by Star Health and Allied Insurance Company Ltd. There is no specific information provided regarding raising capital via new debt issuance or equity offerings during the period covered in the report up to January 29, 2025. The discussions primarily focus on operational performance, regulatory impacts, pricing strategies, loss ratios, product growth, and distribution channels without reference to fundraising plans.

The transcript on page 17 and surrounding pages does not specifically mention any current or future capex, capital investment, or strategic investment plans by Star Health and Allied Insurance Company Ltd. Key points related to strategic focus: - The company is working with the GI Council and major hospital groups to improve billing hygiene and reimbursement processes. - Focus on improving hospital supply and maturity cycles, but no specific investment details are disclosed. - Emphasis on portfolio correction measures, micro-segmentation, and improving retention and fresh business growth. No explicit mention of capital or strategic investments such as capex or partnerships is provided in the disclosed Q&A session.

- The company is experiencing good growth in retail business with expansion in product and distribution profiles. - For the first nine months, there was a 50% volume growth and 50% value growth; Q3 showed around 7% growth in both volume and value for Retail Health. - Fresh retail health business grew by 22% in the first nine months, with retail fresh policy growth at 13%. - Digital fresh business grew by 58%, with "Super Star" product driving fresh growth, becoming a top seller on digital platforms. - The largest premium quarter is expected to be Q4; with price interventions taken in December and January 2025, financials are expected to improve going forward. - The company aims for steady growth, targeting around 15-16% overall with a focus on volume and value growth without compromising renewal persistency. - Continued focus on agency, Banca, corporate, and digital channels expected to support growth.

- Star Health targets doubling its top line by FY28, aiming for around 18% growth annually from FY24 onwards. - Retail fresh business growth has been strong, with 22% growth in 9 months FY25 and 13% volume growth in Q3. - Price hikes across 65% of retail health portfolio (up to Jan 2025) are expected to positively impact loss ratios over the next 18-24 months. - Claims frequency and severity are a challenge, but consistent price increases and corrective underwriting measures aim to improve profitability. - Expense ratio is expected to improve gradually by 0.5-0.75% with scale benefits and "1/N" accounting normalization. - Investment income grew 15% over 9 months to Rs. 996 crore, supporting profitability. - PAT for 9 months FY25 was Rs. 645 crore with PBT of Rs. 862 crore; management aims to maintain positive PAT trajectory. - Solvency ratio is strong at 2.22x, supporting growth plans. - Overall, the company is focused on balanced growth, underwriting discipline, and improving combined ratios to enhance future earnings.

The provided transcript from Star Health and Allied Insurance Company's call does not contain information related to current or expected orderbook or pending orders. The discussion mainly focuses on: - Business growth metrics (retail health, digital, agency, banca, corporate). - Pricing strategies and their impact on loss ratios. - Claims management and hospital industry interaction. - Product launches and renewal persistency. - Regulatory impacts and commission structures. - Preventive measures to contain claims and re-admissions. No data or commentary is provided about orderbook status or pending orders in this transcript.